Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience

OBJECTIVE:To evaluate hematological, cytogenetic and molecular responses as well as the overall, progression-free and event-free survivals of chronic myeloid leukemia patients treated with a third tyrosine kinase inhibitor after failing to respond to imatinib and nilotinib/dasatinib.METHODS:Bone mar...

Full description

Bibliographic Details
Main Authors:	Beatriz Felicio Ribeiro, Eliana C.M. Miranda, Dulcinéia Martins de Albuquerque, Márcia T. Delamain, Gislaine Oliveira-Duarte, Maria Helena Almeida, Bruna Vergílio, Rosana Antunes da Silveira, Vagner Oliveira-Duarte, Irene Lorand-Metze, Carmino A. De Souza, Katia B.B. Pagnano
Format:	Article
Language:	English
Published:	Elsevier España 2015-08-01
Series:	Clinics
Subjects:	CML Dasatinib Nilotinib Third-line TKI treatment
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322015000800550&lng=en&tlng=en

Similar Items

Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
by: Emilio Usala
Published: (2015-10-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics
by: Khalid Alhazzani, et al.
Published: (2023-10-01)

Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors
by: Michael G. Martin, et al.
Published: (2011-12-01)

p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib
by: Hayder M. Al-kuraishy, et al.
Published: (2018-01-01)

A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea
by: Junghoon Shin, et al.
Published: (2018-05-01)

Efficacy of nilotinib in a young patient with high Sokal risk CML Ph+ in treatment failure after high dose imatinib
by: Sabina Russo, et al.
Published: (2015-10-01)

Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase
by: Ibuki Takatsuka, et al.
Published: (2022-01-01)

Debating Frontline Therapy in Chronic Myeloid Leukemia
by: Xia Bi, et al.
Published: (2021-09-01)

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation
by: G Rogers, et al.
Published: (2012-04-01)

Economic evaluation of dasatinib in the treatment of chronic myeloid leukemia patients resistant to imatinib in Chile
by: Milva Caputo, et al.
Published: (2011-04-01)

Resistant Bilateral Chylous Effusion as a Late Adverse Effect of Dasatinib Treatment in Chronic Myeloid Leukaemia
by: Emine Zengin, et al.
Published: (2019-08-01)

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses
by: T Pavey, et al.
Published: (2012-11-01)

Complete molecular response induced by nilotinib in a patient previously treated with imatinib, nilotinib and dasatinib
by: Giuseppe Pietrantuono
Published: (2015-10-01)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
by: Ali Ibrahim, et al.
Published: (2022-05-01)

Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation
by: E Loveman, et al.
Published: (2012-05-01)

Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging
by: Andrea Rodríguez-Agustín, et al.
Published: (2023-03-01)

Atypical presentation of chronic myeloid leukemia with visual disturbance
by: Rachana Chennamaneni, et al.
Published: (2018-01-01)

Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2
by: Sara Galimberti, et al.
Published: (2020-09-01)

HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases
by: Stefano Fiori, et al.
Published: (2021-02-01)

The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia
by: Alessandro Costa, et al.
Published: (2023-07-01)

Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018-08-01)

Nilotinib tedavisi sırasında iki kez iskemik serebrovasküler atak geçiren bir kronik miyeloid lösemi olgusu
by: Gül İLHAN
Published: (2017-09-01)

SIGNIFICANCE OF ADDITIONAL CHROMOSOMAL ABNORMALITIES FOR THE OUTCOMES AFTER THE SECOND LINE NILOTINIB THERAPY IN THE CHRONIC MYELOID LEUKEMIA PATIENTS
by: I. V. Dmytrenko, et al.
Published: (2019-07-01)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
by: Kota Yoshifuji, et al.
Published: (2022-10-01)

A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia
by: Khalid Ahmed, et al.
Published: (2022-12-01)

Nilotinib is effective and well tollerate in patients with multiple comorbidities
by: Carmen Fava, et al.
Published: (2015-10-01)

Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP
by: Küçükyurt Selin, et al.
Published: (2024-02-01)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
by: Nicolas Bradt, et al.
Published: (2022-10-01)

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
by: Olaf Beck, et al.
Published: (2020-03-01)

Dasatinib-Related Chylothorax
by: Yen Min Huang, et al.
Published: (2015-02-01)

Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Inhibition of ABL1 by tyrosine kinase inhibitors leads to a downregulation of MLH1 by Hsp70-mediated lysosomal protein degradation
by: Hannah G. Daniels, et al.
Published: (2022-10-01)

Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study
by: Lu Yu, et al.
Published: (2018-08-01)

Use of nilotinib in the diabetic patient
by: Carmen Tomaselli
Published: (2015-10-01)

Nilotinib after imatinib failure
by: Luca Pezzullo
Published: (2015-10-01)

An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis
by: Burak Uz, et al.
Published: (2016-01-01)

Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease
by: Kevin Peikert, et al.
Published: (2021-05-01)

Peripheral blood CD26 positive leukemic stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia
by: Huda F Ebian, et al.
Published: (2022-01-01)